PDE-5 inhibitors in scleroderma raynaud phenomenon and digital ulcers: Current status of clinical trials

International Journal of Rheumatology

Volumn 2011, Issue , 2011, Pages

  Impens, Ann J ^a   Phillips, Kristine ^a   Schiopu, Elena ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMLODIPINE; PF 00489791; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; UDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

DIASTOLIC BLOOD PRESSURE; DIGITAL ULCER; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; MORBIDITY; PERIPHERAL CIRCULATION; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; ULCER;

EID: 84855295464     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2011/392542     Document Type: Review

References (23)

1. Lin C. S., Lin G., Xin Z. C., Lue T. F., Expression, distribution and regulation of phosphodiesterase 5 Current Pharmaceutical Design 2006 12 27 3439 3457 (Pubitemid 44400482)
2. Wallis R. M., Corbin J. D., Francis S. H., Ellis P., Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro The American Journal of Cardiology 1999 4 3C 12C (Pubitemid 29122752)
3. Zhu B., Zhang L., Alexeyev M., Alvarez D. F., Strada S. J., Stevens T., Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype American Journal of PhysiologyLung Cellular and Molecular Physiology 2009 296 2 L220 L228
4. Wright P. J., Comparison of phosphodiesterase type 5 (PDE5) inhibitors International Journal of Clinical Practice 2006 60 8 967 975 (Pubitemid 44082288)
5. Gali N., Ghofrani H. A., Torbicki A., Barst R. J., Rubin L. J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., Simonneau G., Sildenafil citrate therapy for pulmonary arterial hypertension The New England Journal of Medicine 2005 353 20 2148 2157 (Pubitemid 41653106)
6. Gali N., Brundage B. H., Ghofrani H. A., Oudiz R. J., Simonneau G., Safdar Z., Shapiro S., White R. J., Chan M., Beardsworth A., Frumkin L., Barst R. J., Tadalafil therapy for pulmonary arterial hypertension Circulation 2009 119 22 2894 2903
7. Jing Z., Yu Z., Shen J., Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study American Journal of Respiratory and Critical Care Medicine 2011 183 12 1723 1729
8. Wigley F., Clinical practice. Raynaud's Phenomenon The New England Journal of Medicine 2002 347 1001 1008
9. Schiopu E., Impens A. J., Phillips K., Digital ischemia in scleroderma spectrum of diseases International Journal of Rheumatology 2010 2010 8
10. Jackson G., VardenafilPDE5 inhibitor number 3 International Journal of Clinical Practice 2004 58 3 229
11. Gore J., Silver R., Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis Annals of the Rheumatic Diseases 2005 64 9 1387 (Pubitemid 41206274)
12. Kumar N., Griffiths B., Allen J., Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment The Journal of Rheumatology 2006 33 9 1918 1919 (Pubitemid 44373247)
13. Watanabe H., Nishio S., Ohmae E., Sildenafil improves forearm blood flow in patients with Raynauds phenomenon The European Heart Journal 2004 25 (supplement) 202
14. Fries R., Shariat K., von Wilmowsky H., Bhm M., Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy Circulation 2005 112 19 2980 2985 (Pubitemid 41612301)
15. Brueckner C. S., Becker M. O., Kroencke T., Huscher D., Scherer H. U., Worm M., Burmester G., Riemekasten G., Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study Annals of the Rheumatic Diseases 2010 69 8 1475 1478
16. Caglayan E., Huntgeburth M., Karasch T., Weihrauch J., Hunzelmann N., Krieg T., Erdmann E., Rosenkranz S., Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease Archives of Internal Medicine 2006 166 2 231 233 (Pubitemid 43144949)
17. Baak S., Treatment of Raynaud's phenomena with the PDE-5 inhibitor, Cialis (tadalafil) in patients with scleroderma and lupus Arthritis and Rheumatism 2005 52 S169
18. Friedman E. A., Harris P. A., Wood A. J., Stein C. M., Kurnik D., The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon Clinical Pharmacology Therapeutics 2007 81 4 503 509 (Pubitemid 46452307)
19. Carlino G., Treatment of Raynaud's phenomenon with tadalafil, a phosphodiesterase-5 inhibitor (abstract) Annals of the Rheumatic Diseases 2005 64 258
20. Rosato E., Letizia C., Proietti M., Aversa A., Menghi G., Rossi C., Torella E., Cotesta D., Petramala L., Bruzziches R., Spera G., Pisarri S., Salsano F., Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis Journal of Biological Regulators and Homeostatic Agents 2009 23 1 23 29
21. Schiopu E., Hsu V. M., Impens A. J., Rothman J. A., McCloskey D. A., Wilson J. E., Phillips K., Seibold J. R., Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis The Journal of Rheumatology 2009 36 10 2264 2268
22. Shenoy P. D., Kumar S., Jha L. K., Choudhary S. K., Singh U., Misra R., Agarwal V., Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial Rheumatology 2010 49 12 2420 2428
23. Agarwal V., Ghosh P., Sharma A., Efficacy of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicenter study Arthritis and Rheumatism 2010 62 (supplement) S872